Achilles' heel of cancer?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.The oncologist · 2010
   Trial
2. Exploring natural products as apoptosis modulators in cancers: insights into natural product-based therapeutic strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2025
   Review
3. Expression and Significance of N-myc downstream regulated gene 2 in the process of Esophageal Squamous Cell Carcinogenesis.Bioengineered · 2022
   Article
4. Potential therapeutic targets ofOncotarget · 2018
   Review
5. AAV Infection: Protection from Cancer.Human gene therapy · 2017
   Article
6. p53 as an Effector or Inhibitor of Therapy Response.Cold Spring Harbor perspectives in medicine · 2015
   Review
7. Exposure to the polyester PET precursor--terephthalic acid induces and perpetuates DNA damage-harboring non-malignant human breast cells.Carcinogenesis · 2015
   Article
8. Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.World journal of surgical oncology · 2014
   Article
9. Targeting apoptosis pathways in cancer with alantolactone and isoalantolactone.TheScientificWorldJournal · 2013
   Review
10. Overexpression of the dynein light chain km23-1 in human ovarian carcinoma cells inhibits tumor formation in vivo and causes mitotic delay at prometaphase/metaphase.International journal of cancer · 2011
    Article
11. Ethylenediamine functionalized-single-walled nanotube (f-SWNT)-assisted in vitro delivery of the oncogene suppressor p53 gene to breast cancer MCF-7 cells.International journal of nanomedicine · 2011
    Article
12. A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis.The Biochemical journal · 2009
    Article
13. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.Journal of molecular biology · 2009
    Article
14. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.Molecular and cellular biology · 2007
    Article
15. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.Journal of virology · 2007
    Article
16. Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells.Cancer cell international · 2006
    Article
17. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.Oncogene · 2003
    Article
18. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.Molecular and cellular biology · 2003
    Article
19. The p53 pathway in breast cancer.Breast cancer research : BCR · 2002
    Review

Corrections and comments

• Comment on
  Virus-mediated killing of cells that lack p53 activity.2001

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as